ID   MP2K7_HUMAN             Reviewed;         419 AA.
AC   O14733; B2R9S5; D6W659; O14648; O14816; O60452; O60453; Q1PG43;
AC   Q8IY10;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   30-MAY-2000, sequence version 2.
DT   15-MAR-2017, entry version 170.
DE   RecName: Full=Dual specificity mitogen-activated protein kinase kinase 7;
DE            Short=MAP kinase kinase 7;
DE            Short=MAPKK 7;
DE            EC=2.7.12.2;
DE   AltName: Full=JNK-activating kinase 2;
DE   AltName: Full=MAPK/ERK kinase 7;
DE            Short=MEK 7;
DE   AltName: Full=Stress-activated protein kinase kinase 4;
DE            Short=SAPK kinase 4;
DE            Short=SAPKK-4;
DE            Short=SAPKK4;
DE   AltName: Full=c-Jun N-terminal kinase kinase 2;
DE            Short=JNK kinase 2;
DE            Short=JNKK 2;
GN   Name=MAP2K7; Synonyms=JNKK2, MEK7, MKK7, PRKMK7, SKK4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Heart, and Skeletal muscle;
RX   PubMed=9372971; DOI=10.1128/MCB.17.12.7407;
RA   Wu Z., Wu J., Jacinto E., Karin M.;
RT   "Molecular cloning and characterization of human JNKK2, a novel jun
RT   NH2-terminal kinase-specific kinase.";
RL   Mol. Cell. Biol. 17:7407-7416(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND ENZYME
RP   REGULATION.
RX   PubMed=9312068; DOI=10.1074/jbc.272.40.24751;
RA   Lu X., Nemoto S., Lin A.;
RT   "Identification of c-Jun NH2-terminal protein kinase (JNK)-activating
RT   kinase 2 as an activator of JNK but not p38.";
RL   J. Biol. Chem. 272:24751-24754(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION, TISSUE
RP   SPECIFICITY, AND VARIANT PHE-259.
RC   TISSUE=Fetal kidney;
RX   PubMed=9535930; DOI=10.1074/jbc.273.15.9344;
RA   Foltz I.N., Gerl R.E., Wieler J.S., Luckach M., Salmon R.A.,
RA   Schrader J.W.;
RT   "Human mitogen-activated protein kinase kinase 7 (MKK7) is a highly
RT   conserved c-Jun N-terminal kinase/stress-activated protein kinase
RT   (JNK/SAPK) activated by environmental stresses and physiological
RT   stimuli.";
RL   J. Biol. Chem. 273:9344-9351(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), ENZYME REGULATION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=16442502; DOI=10.1016/j.bbrc.2005.12.223;
RA   Michael L., Swantek J., Robinson M.J.;
RT   "Cloning and expression of human mitogen-activated protein kinase
RT   kinase 7gamma1.";
RL   Biochem. Biophys. Res. Commun. 341:679-683(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION IN
RP   PHOSPHORYLATION OF MAPK8/JNK1 AND MAPK9/JNK2.
RA   Yang J., New L., Yong J., Han J., Su B.;
RT   "Molecular cloning of human JNKK2 reveals a novel kinase module for c-
RT   Jun N-terminal kinase activation.";
RL   Submitted (SEP-1997) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-260 (ISOFORMS 1/4).
RX   PubMed=9207092; DOI=10.1073/pnas.94.14.7337;
RA   Tournier C., Whitmarsh A.J., Cavanagh J., Barrett T., Davis R.J.;
RT   "Mitogen-activated protein kinase kinase 7 is an activator of the c-
RT   Jun NH2-terminal kinase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:7337-7342(1997).
RN   [10]
RP   INTERACTION WITH MAPK8IP1/JIP1 AND MAPK8IP2/JIP2.
RX   PubMed=10490659; DOI=10.1128/MCB.19.10.7245;
RA   Yasuda J., Whitmarsh A.J., Cavanagh J., Sharma M., Davis R.J.;
RT   "The JIP group of mitogen-activated protein kinase scaffold
RT   proteins.";
RL   Mol. Cell. Biol. 19:7245-7254(1999).
RN   [11]
RP   CLEAVAGE BY ANTHRAX LETHAL FACTOR.
RX   PubMed=11104681; DOI=10.1042/bj3520739;
RA   Vitale G., Bernardi L., Napolitani G., Mock M., Montecucco C.;
RT   "Susceptibility of mitogen-activated protein kinase kinase family
RT   members to proteolysis by anthrax lethal factor.";
RL   Biochem. J. 352:739-745(2000).
RN   [12]
RP   INTERACTION WITH MAPK8IP3/JIP3.
RX   PubMed=12189133; DOI=10.1074/jbc.M202004200;
RA   Matsuura H., Nishitoh H., Takeda K., Matsuzawa A., Amagasa T., Ito M.,
RA   Yoshioka K., Ichijo H.;
RT   "Phosphorylation-dependent scaffolding role of JSAP1/JIP3 in the ASK1-
RT   JNK signaling pathway. A new mode of regulation of the MAP kinase
RT   cascade.";
RL   J. Biol. Chem. 277:40703-40709(2002).
RN   [13]
RP   DOMAIN.
RX   PubMed=15866172; DOI=10.1016/j.molcel.2005.04.001;
RA   Takekawa M., Tatebayashi K., Saito H.;
RT   "Conserved docking site is essential for activation of mammalian MAP
RT   kinase kinases by specific MAP kinase kinase kinases.";
RL   Mol. Cell 18:295-306(2005).
RN   [14]
RP   INTERACTION WITH VRK2.
RX   PubMed=18286207; DOI=10.1371/journal.pone.0001660;
RA   Blanco S., Sanz-Garcia M., Santos C.R., Lazo P.A.;
RT   "Modulation of interleukin-1 transcriptional response by the
RT   interaction between VRK2 and the JIP1 scaffold protein.";
RL   PLoS ONE 3:E1660-E1660(2008).
RN   [15]
RP   REVIEW ON ENZYME REGULATION.
RX   PubMed=17496909; DOI=10.1038/sj.onc.1210392;
RA   Raman M., Chen W., Cobb M.H.;
RT   "Differential regulation and properties of MAPKs.";
RL   Oncogene 26:3100-3112(2007).
RN   [16]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [17]
RP   REVIEW ON FUNCTION.
RX   PubMed=20801953; DOI=10.1093/jb/mvq098;
RA   Asaoka Y., Nishina H.;
RT   "Diverse physiological functions of MKK4 and MKK7 during early
RT   embryogenesis.";
RL   J. Biochem. 148:393-401(2010).
RN   [18]
RP   INTERACTION WITH RASSF7.
RX   PubMed=21278800; DOI=10.1038/cdd.2010.137;
RA   Takahashi S., Ebihara A., Kajiho H., Kontani K., Nishina H.,
RA   Katada T.;
RT   "RASSF7 negatively regulates pro-apoptotic JNK signaling by inhibiting
RT   the activity of phosphorylated-MKK7.";
RL   Cell Death Differ. 18:645-655(2011).
RN   [19]
RP   REVIEW ON REGULATION, AND REVIEW ON FUNCTION.
RX   PubMed=21333379; DOI=10.1016/j.ejcb.2010.11.008;
RA   Haeusgen W., Herdegen T., Waetzig V.;
RT   "The bottleneck of JNK signaling: molecular and functional
RT   characteristics of MKK4 and MKK7.";
RL   Eur. J. Cell Biol. 90:536-544(2011).
RN   [20]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-411, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (2.45 ANGSTROMS) OF 101-405.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Crystal structure of human mitogen-activated protein kinase kinase 7
RT   activated mutant (s287d, t291d).";
RL   Submitted (FEB-2009) to the PDB data bank.
RN   [23]
RP   VARIANTS [LARGE SCALE ANALYSIS] SER-118; CYS-138; CYS-162; HIS-162 AND
RP   THR-195.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Dual specificity protein kinase which acts as an
CC       essential component of the MAP kinase signal transduction pathway.
CC       Essential component of the stress-activated protein kinase/c-Jun
CC       N-terminal kinase (SAP/JNK) signaling pathway. With MAP2K4/MKK4,
CC       is the one of the only known kinase to directly activate the
CC       stress-activated protein kinase/c-Jun N-terminal kinases
CC       MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 and
CC       MAP2K7/MKK7 both activate the JNKs by phosphorylation, but they
CC       differ in their preference for the phosphorylation site in the
CC       Thr-Pro-Tyr motif. MAP2K4/MKK4 shows preference for
CC       phosphorylation of the Tyr residue and MAP2K7/MKK7 for the Thr
CC       residue. The monophosphorylation of JNKs on the Thr residue is
CC       sufficient to increase JNK activity indicating that MAP2K7/MKK7 is
CC       important to trigger JNK activity, while the additional
CC       phosphorylation of the Tyr residue by MAP2K4/MKK4 ensures optimal
CC       JNK activation. Has a specific role in JNK signal transduction
CC       pathway activated by proinflammatory cytokines. The MKK/JNK
CC       signaling pathway is also involved in mitochondrial death
CC       signaling pathway, including the release cytochrome c, leading to
CC       apoptosis. {ECO:0000269|PubMed:9312068,
CC       ECO:0000269|PubMed:9372971, ECO:0000269|PubMed:9535930,
CC       ECO:0000269|Ref.5}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- ENZYME REGULATION: Activated by phosphorylation by specific MAP
CC       kinase kinase kinases such as MAP3K1/MEKK1, MAP3K3/MEKK3,
CC       MAP3K11/MLK3 and MAP3K12/DLK. {ECO:0000269|PubMed:16442502,
CC       ECO:0000269|PubMed:9312068}.
CC   -!- SUBUNIT: Interacts with isoform 1 of VRK2. Interacts (via its D
CC       domain) with its substrates MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3
CC       (By similarity). Interacts (via its DVD domain) with MAP3Ks
CC       activators like MAP3K5/ASK1 and MAP3K1/MEKK1 (By similarity).
CC       Interacts with MAPK8IP1/JIP1, MAPK8IP2/JIP2 and MAPK8IP3/JIP3
CC       scaffold proteins. Interacts with RASSF7, the interaction promotes
CC       phosphorylation. {ECO:0000250, ECO:0000269|PubMed:10490659,
CC       ECO:0000269|PubMed:12189133, ECO:0000269|PubMed:18286207,
CC       ECO:0000269|PubMed:21278800}.
CC   -!- INTERACTION:
CC       O15519-1:CFLAR; NbExp=2; IntAct=EBI-492605, EBI-4567563;
CC       O75293:GADD45B; NbExp=8; IntAct=EBI-492605, EBI-448187;
CC       Q5S007:LRRK2; NbExp=3; IntAct=EBI-492605, EBI-5323863;
CC       O43318:MAP3K7; NbExp=3; IntAct=EBI-492605, EBI-358684;
CC       P45983:MAPK8; NbExp=4; IntAct=EBI-492605, EBI-286483;
CC       Q9UQF2:MAPK8IP1; NbExp=5; IntAct=EBI-492605, EBI-78404;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=A;
CC         IsoId=O14733-1; Sequence=Displayed;
CC       Name=2; Synonyms=B;
CC         IsoId=O14733-2; Sequence=VSP_004883;
CC         Note=May be due to intron retention.;
CC       Name=3; Synonyms=gamma1;
CC         IsoId=O14733-3; Sequence=VSP_022309;
CC       Name=4;
CC         IsoId=O14733-4; Sequence=VSP_022310;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Ubiquitous; with highest level of expression
CC       in skeletal muscle. Isoform 3 is found at low levels in placenta,
CC       fetal liver, and skeletal muscle. {ECO:0000269|PubMed:16442502,
CC       ECO:0000269|PubMed:9372971, ECO:0000269|PubMed:9535930}.
CC   -!- DOMAIN: The DVD domain (residues 377-400) contains a conserved
CC       docking site and is found in the mammalian MAP kinase kinases
CC       (MAP2Ks). The DVD sites bind to their specific upstream MAP kinase
CC       kinase kinases (MAP3Ks) and are essential for activation.
CC       {ECO:0000269|PubMed:15866172}.
CC   -!- DOMAIN: The D domain (residues 37-57) contains a conserved docking
CC       site and is required for the binding to MAPK substrates.
CC       {ECO:0000269|PubMed:15866172}.
CC   -!- PTM: Activated by phosphorylation on Ser-271 and Thr-275 by MAP
CC       kinase kinase kinases (MAP3Ks). {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. MAP kinase kinase subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB97813.1; Type=Erroneous termination; Positions=420; Note=Translated as stop.; Evidence={ECO:0000305};
CC       Sequence=AAB97813.1; Type=Frameshift; Positions=402, 410; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF014401; AAB88048.1; -; mRNA.
DR   EMBL; AF006689; AAB97813.1; ALT_SEQ; mRNA.
DR   EMBL; AF013588; AAC16272.1; -; mRNA.
DR   EMBL; AF013589; AAC16273.1; -; mRNA.
DR   EMBL; DQ445915; ABE03013.1; -; mRNA.
DR   EMBL; AF022805; AAC26142.1; -; mRNA.
DR   EMBL; AK313899; BAG36622.1; -; mRNA.
DR   EMBL; CH471139; EAW68964.1; -; Genomic_DNA.
DR   EMBL; CH471139; EAW68968.1; -; Genomic_DNA.
DR   EMBL; BC038295; AAH38295.1; -; mRNA.
DR   EMBL; AF003199; AAB63374.1; -; mRNA.
DR   CCDS; CCDS42491.1; -. [O14733-1]
DR   CCDS; CCDS74277.1; -. [O14733-3]
DR   CCDS; CCDS74278.1; -. [O14733-4]
DR   RefSeq; NP_001284484.1; NM_001297555.1. [O14733-3]
DR   RefSeq; NP_001284485.1; NM_001297556.1. [O14733-4]
DR   RefSeq; NP_660186.1; NM_145185.3. [O14733-1]
DR   UniGene; Hs.531754; -.
DR   PDB; 2DYL; X-ray; 2.45 A; A=101-405.
DR   PDB; 3WZU; X-ray; 3.01 A; A=103-419.
DR   PDB; 4UX9; X-ray; 2.34 A; F/G/H/I=37-48.
DR   PDB; 5B2K; X-ray; 2.75 A; A=103-419.
DR   PDB; 5B2L; X-ray; 2.10 A; A=103-419.
DR   PDB; 5B2M; X-ray; 3.06 A; A=103-419.
DR   PDBsum; 2DYL; -.
DR   PDBsum; 3WZU; -.
DR   PDBsum; 4UX9; -.
DR   PDBsum; 5B2K; -.
DR   PDBsum; 5B2L; -.
DR   PDBsum; 5B2M; -.
DR   DisProt; DP00841; -.
DR   ProteinModelPortal; O14733; -.
DR   SMR; O14733; -.
DR   BioGrid; 111595; 57.
DR   IntAct; O14733; 24.
DR   MINT; MINT-1378223; -.
DR   STRING; 9606.ENSP00000381066; -.
DR   BindingDB; O14733; -.
DR   ChEMBL; CHEMBL3530; -.
DR   GuidetoPHARMACOLOGY; 2068; -.
DR   iPTMnet; O14733; -.
DR   PhosphoSitePlus; O14733; -.
DR   BioMuta; MAP2K7; -.
DR   EPD; O14733; -.
DR   MaxQB; O14733; -.
DR   PaxDb; O14733; -.
DR   PeptideAtlas; O14733; -.
DR   PRIDE; O14733; -.
DR   DNASU; 5609; -.
DR   Ensembl; ENST00000397979; ENSP00000381066; ENSG00000076984. [O14733-1]
DR   Ensembl; ENST00000397981; ENSP00000381068; ENSG00000076984. [O14733-4]
DR   Ensembl; ENST00000397983; ENSP00000381070; ENSG00000076984. [O14733-3]
DR   GeneID; 5609; -.
DR   KEGG; hsa:5609; -.
DR   UCSC; uc002mit.4; human. [O14733-1]
DR   CTD; 5609; -.
DR   DisGeNET; 5609; -.
DR   GeneCards; MAP2K7; -.
DR   HGNC; HGNC:6847; MAP2K7.
DR   HPA; CAB004262; -.
DR   HPA; HPA001633; -.
DR   HPA; HPA064711; -.
DR   MIM; 603014; gene.
DR   neXtProt; NX_O14733; -.
DR   OpenTargets; ENSG00000076984; -.
DR   PharmGKB; PA284; -.
DR   eggNOG; KOG0983; Eukaryota.
DR   eggNOG; ENOG410XTNQ; LUCA.
DR   GeneTree; ENSGT00760000119199; -.
DR   HOVERGEN; HBG108518; -.
DR   InParanoid; O14733; -.
DR   KO; K04431; -.
DR   OMA; HAPSSAY; -.
DR   OrthoDB; EOG091G0A9H; -.
DR   PhylomeDB; O14733; -.
DR   TreeFam; TF350701; -.
DR   BRENDA; 2.7.12.2; 2681.
DR   Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence.
DR   Reactome; R-HSA-2871796; FCERI mediated MAPK activation.
DR   Reactome; R-HSA-450321; JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1.
DR   Reactome; R-HSA-5210891; Uptake and function of anthrax toxins.
DR   SignaLink; O14733; -.
DR   SIGNOR; O14733; -.
DR   ChiTaRS; MAP2K7; human.
DR   EvolutionaryTrace; O14733; -.
DR   GeneWiki; MAP2K7; -.
DR   GenomeRNAi; 5609; -.
DR   PMAP-CutDB; O14733; -.
DR   PRO; PR:O14733; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; ENSG00000076984; -.
DR   CleanEx; HS_MAP2K7; -.
DR   Genevisible; O14733; HS.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0004708; F:MAP kinase kinase activity; IDA:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0019903; F:protein phosphatase binding; ISS:BHF-UCL.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004702; F:signal transducer, downstream of receptor, with serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0007257; P:activation of JUN kinase activity; ISS:BHF-UCL.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007254; P:JNK cascade; TAS:Reactome.
DR   GO; GO:0051973; P:positive regulation of telomerase activity; IMP:BHF-UCL.
DR   GO; GO:1904355; P:positive regulation of telomere capping; IMP:BHF-UCL.
DR   GO; GO:0032212; P:positive regulation of telomere maintenance via telomerase; IMP:BHF-UCL.
DR   GO; GO:0035897; P:proteolysis in other organism; TAS:Reactome.
DR   GO; GO:0009408; P:response to heat; IDA:UniProtKB.
DR   GO; GO:0006970; P:response to osmotic stress; IDA:UniProtKB.
DR   GO; GO:0034612; P:response to tumor necrosis factor; IDA:UniProtKB.
DR   GO; GO:0009411; P:response to UV; IDA:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0051403; P:stress-activated MAPK cascade; IDA:UniProtKB.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Apoptosis;
KW   ATP-binding; Coiled coil; Complete proteome; Cytoplasm; Kinase;
KW   Magnesium; Metal-binding; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Serine/threonine-protein kinase;
KW   Stress response; Transferase; Tyrosine-protein kinase.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22814378}.
FT   CHAIN         2    419       Dual specificity mitogen-activated
FT                                protein kinase kinase 7.
FT                                /FTId=PRO_0000086388.
FT   DOMAIN      120    380       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     126    134       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION       37     57       D domain. {ECO:0000250}.
FT   REGION      377    400       DVD domain.
FT   COILED        2     30       {ECO:0000255}.
FT   ACT_SITE    243    243       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     149    149       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   SITE         44     45       Cleavage; by anthrax lethal factor.
FT   SITE         76     77       Cleavage; by anthrax lethal factor.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22814378}.
FT   MOD_RES     271    271       Phosphoserine; by MAP3K. {ECO:0000250}.
FT   MOD_RES     275    275       Phosphothreonine; by MAP3K.
FT                                {ECO:0000250}.
FT   MOD_RES     411    411       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ      42     42       T -> IIVITLSPAPAPSQRAA (in isoform 3).
FT                                {ECO:0000303|PubMed:16442502}.
FT                                /FTId=VSP_022309.
FT   VAR_SEQ     111    111       Q -> QVPPSLWRGEGGGPARLDPSWERQWGAGGGGRAPGT
FT                                LQPSLSSQ (in isoform 2).
FT                                {ECO:0000303|PubMed:9535930}.
FT                                /FTId=VSP_004883.
FT   VAR_SEQ     312    312       L -> LPCPSPSQ (in isoform 4).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_022310.
FT   VARIANT     118    118       N -> S (in dbSNP:rs56316660).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040825.
FT   VARIANT     138    138       R -> C (in dbSNP:rs56106612).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040826.
FT   VARIANT     162    162       R -> C (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040827.
FT   VARIANT     162    162       R -> H (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040828.
FT   VARIANT     195    195       A -> T (in dbSNP:rs55800262).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040829.
FT   VARIANT     259    259       L -> F (in dbSNP:rs1053566).
FT                                {ECO:0000269|PubMed:9535930}.
FT                                /FTId=VAR_029890.
FT   CONFLICT     94     94       Q -> H (in Ref. 2; AAB97813).
FT                                {ECO:0000305}.
FT   CONFLICT    106    106       L -> P (in Ref. 4; ABE03013).
FT                                {ECO:0000305}.
FT   CONFLICT    133    133       Q -> P (in Ref. 2; AAB97813).
FT                                {ECO:0000305}.
FT   CONFLICT    142    142       T -> N (in Ref. 1; AAB88048).
FT                                {ECO:0000305}.
FT   CONFLICT    407    407       S -> N (in Ref. 2; AAB97813).
FT                                {ECO:0000305}.
FT   CONFLICT    415    415       L -> LG (in Ref. 2; AAB97813).
FT                                {ECO:0000305}.
FT   STRAND      105    108       {ECO:0000244|PDB:5B2L}.
FT   STRAND      111    114       {ECO:0000244|PDB:5B2L}.
FT   HELIX       117    119       {ECO:0000244|PDB:5B2L}.
FT   STRAND      120    127       {ECO:0000244|PDB:5B2L}.
FT   STRAND      129    131       {ECO:0000244|PDB:5B2L}.
FT   STRAND      134    139       {ECO:0000244|PDB:5B2L}.
FT   TURN        140    142       {ECO:0000244|PDB:5B2L}.
FT   STRAND      145    152       {ECO:0000244|PDB:5B2L}.
FT   HELIX       157    172       {ECO:0000244|PDB:5B2L}.
FT   TURN        173    175       {ECO:0000244|PDB:5B2L}.
FT   STRAND      182    187       {ECO:0000244|PDB:5B2L}.
FT   STRAND      189    196       {ECO:0000244|PDB:5B2L}.
FT   STRAND      200    202       {ECO:0000244|PDB:5B2L}.
FT   HELIX       203    210       {ECO:0000244|PDB:5B2L}.
FT   HELIX       216    237       {ECO:0000244|PDB:5B2L}.
FT   HELIX       246    248       {ECO:0000244|PDB:5B2L}.
FT   STRAND      249    251       {ECO:0000244|PDB:5B2L}.
FT   STRAND      257    259       {ECO:0000244|PDB:5B2L}.
FT   TURN        262    265       {ECO:0000244|PDB:5B2L}.
FT   HELIX       281    283       {ECO:0000244|PDB:5B2L}.
FT   HELIX       286    289       {ECO:0000244|PDB:5B2L}.
FT   STRAND      292    297       {ECO:0000244|PDB:5B2L}.
FT   HELIX       302    317       {ECO:0000244|PDB:5B2L}.
FT   TURN        321    324       {ECO:0000244|PDB:2DYL}.
FT   HELIX       328    337       {ECO:0000244|PDB:5B2L}.
FT   STRAND      345    347       {ECO:0000244|PDB:2DYL}.
FT   HELIX       351    360       {ECO:0000244|PDB:5B2L}.
FT   HELIX       365    367       {ECO:0000244|PDB:5B2L}.
FT   HELIX       371    374       {ECO:0000244|PDB:5B2L}.
FT   HELIX       378    385       {ECO:0000244|PDB:5B2L}.
FT   HELIX       390    400       {ECO:0000244|PDB:5B2L}.
SQ   SEQUENCE   419 AA;  47485 MW;  F1B22E050F54299A CRC64;
     MAASSLEQKL SRLEAKLKQE NREARRRIDL NLDISPQRPR PTLQLPLAND GGSRSPSSES
     SPQHPTPPAR PRHMLGLPST LFTPRSMESI EIDQKLQEIM KQTGYLTIGG QRYQAEINDL
     ENLGEMGSGT CGQVWKMRFR KTGHVIAVKQ MRRSGNKEEN KRILMDLDVV LKSHDCPYIV
     QCFGTFITNT DVFIAMELMG TCAEKLKKRM QGPIPERILG KMTVAIVKAL YYLKEKHGVI
     HRDVKPSNIL LDERGQIKLC DFGISGRLVD SKAKTRSAGC AAYMAPERID PPDPTKPDYD
     IRADVWSLGI SLVELATGQF PYKNCKTDFE VLTKVLQEEP PLLPGHMGFS GDFQSFVKDC
     LTKDHRKRPK YNKLLEHSFI KRYETLEVDV ASWFKDVMAK TESPRTSGVL SQPHLPFFR
//
